W. Blair

发表

Utilization of a mammalian cell-based RNA binding assay to characterize the RNA binding properties of picornavirus 3C proteinases.

B. Cullen, B. Semler, W. Blair, 1998, RNA.

A mutant poliovirus containing a novel proteolytic cleavage site in VP3 is altered in viral maturation

B. Semler, W. Blair, S. Hwang, 1990, Journal of virology.

A genetic locus in mutant poliovirus genomes involved in overproduction of RNA polymerase and 3C proteinase.

B. Semler, W. Blair, P. G. Dewalt, 1990, Virology.

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

J. Nieman, S. Butler, G. Ciaramella, 2010, PLoS pathogens.

Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.

Adam R. Johnson, Jun Liang, J. DeVoss, 2013, Journal of medicinal chemistry.

Lead identification of novel and selective TYK2 inhibitors.

Adam R. Johnson, Jun Liang, M. Ultsch, 2013, European journal of medicinal chemistry.

A new regulatory switch in a JAK protein kinase

Charles Eigenbrot, Vickie Tsui, Paul Gibbons, 2011, Proteins.

Compensatory Substitutions in the HIV-1 Capsid Reduce the Fitness Cost Associated with Resistance to a Capsid-Targeting Small-Molecule Inhibitor

S. Butler, C. Aiken, W. Blair, 2014, Journal of Virology.

5th Antiviral Drug Discovery and Development Summit.

W. Blair, M. Perros, 2004, Expert opinion on investigational drugs.

Identification of regions in HIV-1 Nef required for efficient downregulation of cell surface CD4.

B. Cullen, R. Truant, W. Blair, 1997, Virology.

Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.

Jane R Kenny, Michael Siu, Deepak Sampath, 2012, Journal of medicinal chemistry.

Abstract A20: Development and validation of a novel acute myeloid leukemia xenograft model that is dependent on the JAK2V617F mutation for growth in vivo

Leslie B. Lee, Christine Chang, D. Sampath, 2009 .

Mutational analysis of the transcription activation domain of RelA: identification of a highly synergistic minimal acidic activation module

B. Cullen, S. Madore, W. Blair, 1994, Molecular and cellular biology.

Current Landscape of Antiviral Drug Discovery

Christopher D. Cox, W. Blair, 2016, F1000Research.

Identification and Functional Characterization of a High-Affinity Bel-1 DNA Binding Site Located in the Human Foamy Virus Internal Promoter

B. Cullen, Yibin Kang, W. Blair, 1998, Journal of Virology.

Mutational Analysis of the Transcription Activation Domain

W. Blair, '. H. P. Bogerd, '. S. J. Madore, 2022 .

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Matthew J. Davis, R. Yelensky, D. Carbone, 2022, Nature Medicine.

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.

Adam R. Johnson, Jun Liang, J. DeVoss, 2017, Bioorganic & medicinal chemistry letters.

Revealed by Novel TYK2-Selective Inhibitors Activity in Human Cytokine Responses A Restricted Role for TYK2 Catalytic

Adam R. Johnson, N. Lewin-Koh, Lawren C. Wu, 2013 .

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis

R. Hotchkiss, S. Krishnan, J. Suzich, 2014, Critical Care.

3CD Cleavage of the Poliovirus P1 Precursor: A Model for Complex Proteinase/Substrate Interactions

B. Semler, Xiaoyu Li, W. Blair, 1993 .

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

D. Hazuda, M. Swanson, D. Graham, 2017, JCI insight.

Role for the P4 amino acid residue in substrate utilization by the poliovirus 3CD proteinase

B. Semler, W. Blair, 1991, Journal of virology.

Identification and Functional Characterization of a High-Affinity Bel-1 DNA Binding Site Located in the Human Foamy Virus Internal Promoter

B. Cullen, Yibin Kang, W. Blair, 1998, Journal of Virology.

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys

R. Geleziunas, D. Barouch, W. Blair, 2022, PLoS pathogens.

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.

Zheng Yang, Fang Zhao, Timothy P Spicer, 2003, Journal of medicinal chemistry.

Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.

Bohdan Waszkowycz, Jane R Kenny, Charles Eigenbrot, 2012, Journal of medicinal chemistry.

2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.

M. Ultsch, C. Eigenbrot, Leslie B. Lee, 2013, Bioorganic & medicinal chemistry letters.

A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors

Adam R. Johnson, Jun Liang, N. Lewin-Koh, 2013, The Journal of Immunology.

A survey of core replacements in indole-based HIV-1 attachment inhibitors.

T. Spicer, N. Meanwell, P. Shi, 2019, Bioorganic & medicinal chemistry letters.

Inhibition of HIV-1 protease by a boron-modified polypeptide.

W. Prusoff, W. Blair, K. Guo, 2000, Biochemical pharmacology.

High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full Replication Assay That Includes HIV-1 Vif as an Antiviral Target

W. Blair, A. Patick, Joan Q. Cao, 2005, Antimicrobial Agents and Chemotherapy.

Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors.

S. Butler, W. Blair, G. Nakayama, 2005, Antiviral research.

A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors.

W. Blair, A. Patick, Joan Q. Cao, 2005, Antiviral research.

Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.

Jane R Kenny, Charles Eigenbrot, Micah Steffek, 2013, Bioorganic & medicinal chemistry letters.

Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives.

T. Spicer, N. Meanwell, P. Shi, 2009, Bioorganic & medicinal chemistry letters.

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations

Min Xu, D. Hazuda, M. Lai, 2016, Antimicrobial Agents and Chemotherapy.

Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.

Adam R. Johnson, H. Dyke, Rohan V Mendonca, 2013, Bioorganic & medicinal chemistry letters.

BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

David A. Stock, R. Colonno, W. Blair, 2000, Antimicrobial Agents and Chemotherapy.

Genetic analysis indicates that the human foamy virus Bel-1 protein contains a transcription activation domain of the acidic class

B. Cullen, W. Blair, H. Bogerd, 1994, Journal of virology.

Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus

B. Cullen, W. Blair, H. Bogerd, 1993, Journal of virology.

Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Ignacio Aliagas, 2013, Journal of medicinal chemistry.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Tian Jin, 2012, Journal of medicinal chemistry.

Infection and Propagation of Human Rhinovirus C in Human Airway Epithelial Cells

N. Patel, Qing Zhu, Susan D. Wilson, 2012, Journal of Virology.

Long-acting capsid inhibitor protects macaques from repeat SHIV challenges

R. Geleziunas, S. Yant, T. Cihlar, 2021, Nature.

Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation

D. Hazuda, A. Webber, D. Tellers, 2017, Antiviral research.

The human foamy virus Bel-1 transcription factor is a sequence-specific DNA binding protein

B. Cullen, J. Fukushima, W. Blair, 1996, Journal of virology.

A yeast TATA-binding protein mutant that selectively enhances gene expression from weak RNA polymerase II promoters

B. Cullen, W. Blair, B R Cullen, 1997, Molecular and cellular biology.

A Broadly Neutralizing Human Monoclonal Antibody Directed against a Novel Conserved Epitope on the Influenza Virus H3 Hemagglutinin Globular Head

Qing Zhu, J. McAuliffe, F. Palmer-Hill, 2014, Journal of Virology.

Self-cleaving proteases.

B. Semler, W. Blair, 1991, Current opinion in cell biology.

5th Antiviral Drug Discovery & Development Summit

W. Blair, M. Perros, 2004 .

Genetic Evidence that theTatProteins ofHuman Immunodeficiency Virus Types1and2CanMultimerize intheEukaryotic CellNucleus

B. Cullen, W. Blair, H. Bogerd, 1993 .

New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation

S. Butler, W. Blair, A. Patick, 2009, Antimicrobial Agents and Chemotherapy.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Charles Eigenbrot, 2012, Bioorganic & medicinal chemistry letters.

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

Zheng Yang, Tao Wang, Robert Fridell, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns.

T. Spicer, N. Meanwell, P. Shi, 2009, Bioorganic & medicinal chemistry letters.

Identification and Characterization of UK-201844, a Novel Inhibitor That Interferes with Human Immunodeficiency Virus Type 1 gp160 Processing

S. Butler, W. Blair, A. Patick, 2007, Antimicrobial Agents and Chemotherapy.

A cellular cofactor facilitates efficient 3CD cleavage of the poliovirus P1 precursor

B. Semler, X. Li, W. Blair, 1993, Journal of virology.

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV

P. Bieniasz, J. Lifson, R. Gorelick, 2023, EBioMedicine.

A new regulatory switch in a JAK protein kinase

Jun Liang, M. Ultsch, M. Lamers, 2011, Proteins.

Developing and applying ultrasensitive p24 protein immunoassay for HIV latency

D. Hazuda, M. Swanson, D. Graham, 2015 .

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Adam R. Johnson, Rohan V Mendonca, M. Ultsch, 2012, Bioorganic & medicinal chemistry letters.